+

WO1999019330A1 - Nouveaux composes de cephem - Google Patents

Nouveaux composes de cephem Download PDF

Info

Publication number
WO1999019330A1
WO1999019330A1 PCT/JP1998/004520 JP9804520W WO9919330A1 WO 1999019330 A1 WO1999019330 A1 WO 1999019330A1 JP 9804520 W JP9804520 W JP 9804520W WO 9919330 A1 WO9919330 A1 WO 9919330A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
amino
salt
group
formula
Prior art date
Application number
PCT/JP1998/004520
Other languages
English (en)
Japanese (ja)
Inventor
Kohji Kawabata
Toshio Yamanaka
Minoru Sakurai
Kohei Kishi
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Publication of WO1999019330A1 publication Critical patent/WO1999019330A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Definitions

  • R 7 represents amino or protected amino; or a group represented by the formula:
  • Z represents a leaving group
  • organic acid addition salt for example, formate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, p (I) Toluenesulfonate
  • inorganic acid addition salts eg, hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate
  • “Lower” means a group having 1-6 carbon atoms, preferably 1-4 carbon atoms, unless otherwise specified.
  • a suitable phenyl (lower) alkoxycarbonyl (eg, benzyloxycarbonyl, phenethyloxycarbonyl, p-ditrobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl) May have a substituent Caryl (lower) alkoxycarbonyl, ceenyl acetyl, imidazolyl acetyl, furyl acetyl, tetrazolyl acetyl, triazolyl acetyl, thiadia azolyl acetyl, chenyl propionyl, thiadia zolyl propionyl Lower alkylsulfonyl (eg, methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, pentylsulfonyl), aryls
  • Saturated 3 to 8 membered (more preferably 4 to 7 member, more preferably 5 to 7 membered) heterocyclic group containing 1 to 4 nitrogen atoms, for example perhydroazepinyl (for example perhydro- 1H-azepinyl), pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, azetidinyl and the like;
  • heterocycle moiety in the “heterocycle or heterocycle (lower) alkyl containing a hydrogen atom bonded to a waterline atom in the heterocycle moiety” include the following.
  • R 2 is hydrogen or lower alkyl
  • R 5 represents amino, R e represents halogen
  • R 2 is hydrogen or lower alkyl
  • Suitable reactive derivatives at the amino group of compound [II] include a Schiff base imino formed by the reaction of compound [II] with a carbonyl compound such as an aldehyde or ketone, or a tautomeric enamine type isomer.
  • Compounds [II] and silyl derivatives formed by the reaction of silyl compounds such as bis (trimethylsilyl) acetamide, mono (trimethylsilyl) acetamide or bis (trimethylsilyl) urea; compounds Derivatives formed by the reaction of [II] with phosphorus trichloride or phosgene.
  • Cipyrrolidine (6.96 g) was obtained.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des composés de céphem, ou leurs sels, à activité antibactérienne de formule (I) où R1 représente un groupe correspondant à l'une des formules (a), (b), (c) suivantes (dans lesquelles, R?5, R7 et R8¿ représentent chacun amino ou un groupe amino protégé, et R6 représente halogéno); R2 représente H ou alkyle inférieur; R3 représente un groupe hétérocyclique, alkyle (inférieur) substitué par un hétérocycle, amino alkyle (inférieur), alkyle (inférieur) substitué par un amino N-substitué, alkyle (inférieur) di-substitué par un amino N, N-substitué, ou un groupe de formule générale (d) dans lequel R4 représente carboxy, ou un groupe carboxy protégé.
PCT/JP1998/004520 1997-10-10 1998-10-06 Nouveaux composes de cephem WO1999019330A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO9732 1997-10-10
AUPO9732A AUPO973297A0 (en) 1997-10-10 1997-10-10 New compound

Publications (1)

Publication Number Publication Date
WO1999019330A1 true WO1999019330A1 (fr) 1999-04-22

Family

ID=3804012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/004520 WO1999019330A1 (fr) 1997-10-10 1998-10-06 Nouveaux composes de cephem

Country Status (2)

Country Link
AU (1) AUPO973297A0 (fr)
WO (1) WO1999019330A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100453713B1 (ko) * 2002-02-28 2004-10-20 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59130292A (ja) * 1982-12-06 1984-07-26 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物
JPH06135972A (ja) * 1992-09-08 1994-05-17 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物
JPH0733777A (ja) * 1993-07-16 1995-02-03 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物
JPH07196665A (ja) * 1993-12-15 1995-08-01 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物
JPH08337585A (ja) * 1995-01-30 1996-12-24 Takeda Chem Ind Ltd セフェム化合物、その製造法および抗菌組成物
JPH0948785A (ja) * 1995-05-29 1997-02-18 Takeda Chem Ind Ltd セフェム化合物、その製造法および抗菌組成物
WO1997012890A1 (fr) * 1995-09-29 1997-04-10 Fujisawa Pharmaceutical Co., Ltd. Nouveaux composes de cepheme
JPH09100283A (ja) * 1995-07-19 1997-04-15 Takeda Chem Ind Ltd セフェム化合物、その製造法および抗菌組成物
JPH10265488A (ja) * 1997-03-27 1998-10-06 Takeda Chem Ind Ltd ホスフォノセフェム誘導体

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59130292A (ja) * 1982-12-06 1984-07-26 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物
JPH06135972A (ja) * 1992-09-08 1994-05-17 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物
JPH0733777A (ja) * 1993-07-16 1995-02-03 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物
JPH07196665A (ja) * 1993-12-15 1995-08-01 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物
JPH08337585A (ja) * 1995-01-30 1996-12-24 Takeda Chem Ind Ltd セフェム化合物、その製造法および抗菌組成物
JPH0948785A (ja) * 1995-05-29 1997-02-18 Takeda Chem Ind Ltd セフェム化合物、その製造法および抗菌組成物
JPH09100283A (ja) * 1995-07-19 1997-04-15 Takeda Chem Ind Ltd セフェム化合物、その製造法および抗菌組成物
WO1997012890A1 (fr) * 1995-09-29 1997-04-10 Fujisawa Pharmaceutical Co., Ltd. Nouveaux composes de cepheme
JPH10265488A (ja) * 1997-03-27 1998-10-06 Takeda Chem Ind Ltd ホスフォノセフェム誘導体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100453713B1 (ko) * 2002-02-28 2004-10-20 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject

Also Published As

Publication number Publication date
AUPO973297A0 (en) 1997-11-06

Similar Documents

Publication Publication Date Title
AU2015371294B2 (en) Compounds, compositions, and methods for increasing CFTR activity
CN106967066B (zh) 新型β-内酰胺酶抑制剂及其制备方法
AU2008319266B2 (en) Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase
CA3224249A1 (fr) Compose destine a etre utilise en tant qu'inhibiteur de kif18a
AU2020355358A1 (en) PROTAC small molecule compound and application thereof
CN112566916B (zh) 作为pad4抑制剂的经取代的噻吩并吡咯
BR112020003725A2 (pt) inibição da peptidase 30 específica de ubiquitina
US20100113502A1 (en) Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands
EP3538526A1 (fr) Composés mono et spirocycliques contenant du cyclobutane et de l'azétidine en tant qu'inhibiteurs de l'intégrine alpha v
CA2992408A1 (fr) Composes aza substitues comme inhibiteurs de l'irak-4
AU2008237660A1 (en) 3-amido-pyrrolo [3, 4-C] pyrazole-5 (1H, 4H, 6H) carbaldehyde derivatives as inhibitors of protein kinase C
PT88422B (pt) Processo para a preparacao de tiadiazois uteis no tratamento de demencia
WO2022165513A1 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
CA3199496A1 (fr) Derives heterocycliques pour le traitement de troubles a mediation par trpm3
KR20240062147A (ko) P53의 돌연변이체를 표적으로 하는 화합물
WO2019118528A1 (fr) Modulateurs de progranuline et leurs procédés d'utilisation
EP4376840A1 (fr) Dérivés de pyridine substitués en tant qu'inhibiteurs de sarm1
EP3927699A1 (fr) Modulateurs de la protéine proto-oncogène de la famille myc
US20090099157A1 (en) Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s
AU2002215212B2 (en) 1-methylcarbapenem derivatives
US20240025924A1 (en) Heterocycle substituted ketone derivative, and composition and medicinal use thereof
KR20230012582A (ko) 아제티딘 환형 우레아
WO1999019330A1 (fr) Nouveaux composes de cephem
CA3217694A1 (fr) Compose heterocyclique contenant de l'azote, son procede de preparation et son application
AU2005272298A1 (en) Pyrazolo[1,5-a]pyrimidine derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): BR CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载